Axsome Therapeutics (AXSM) Inventory Average (2022 - 2026)

Axsome Therapeutics has reported Inventory Average for 5 years, with the latest figure at $29.7 million in Q1 2026.

• Quarterly Inventory Average rose 85.49% year-over-year to $29.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29.7 million (up 85.49% YoY) and the FY2025 annual result came in at $21.8 million, up 41.48% from the prior year.
• Inventory Average grew to $29.7 million in Q1 2026 per AXSM's latest filing, from $25.9 million in the prior quarter.
• Over five years, Inventory Average peaked at $29.7 million in Q1 2026 and troughed at $6.1 million in Q1 2023.
• A 5-year average of $16.0 million and a median of $15.0 million in 2024 frame the typical range for Inventory Average.
• The sharpest annual moves came in 2024 and 2025: Inventory Average surged 240.23% in 2024, then retreated 23.16% in 2025.
• Over 5 years, Inventory Average stood at $9.2 million in 2022, then jumped by 37.21% to $12.6 million in 2023, then rose by 19.41% to $15.0 million in 2024, then surged by 72.39% to $25.9 million in 2025, then climbed by 14.97% to $29.7 million in 2026.
• According to Business Quant data, Inventory Average over the past three periods registered $29.7 million, $25.9 million, and $21.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.